Breast cancer (invasive) · line 1 · Olaparib monotherapy (BRCA-mutant HER2- breast: metastatic OR adjuvant high-risk early)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-OLAPARIB-BREAST`

ID	`IND-BREAST-BRCA-POS-MET-PARPI`
Type	Indication
Status	pending_clinical_signoff
Diseases	`DIS-BREAST`
Sources	`SRC-ESMO-BREAST-METASTATIC-2024` `SRC-NCCN-BREAST-2025`

Notes

OlympiAD: olaparib superior to physician-choice chemo in germline BRCA-mutant HER2- metastatic. Talazoparib (EMBRACA) similar efficacy with different AE profile (more anemia). Sequencing relative to CDK4/6i (HR+ subset) and chemoimmunotherapy (TNBC subset) per clinical context.

Used By

Algorithms

ALGO-BREAST-1L - ALGO-BREAST-1L
ALGO-BREAST-HR-POS-2L - ALGO-BREAST-HR-POS-2L

Regimen

REG-PEMBRO-CHEMO-TNBC-MET - Pembrolizumab + chemotherapy (TNBC, metastatic PD-L1+)